Evidence map›Paper›PMID 34625113›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Alloantigen-activated (AAA) CD4

Kazuhiro Mochizuki, Shogo Kobayashi, Nobuhisa Takahashi, Kotaro Sugimoto, Hideki Sano, Yoshihiro Ohara, Shin Mineishi, Yi Zhang, Atsushi Kikuta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Harnessing allogeneic CD4Fukushima journal of medical science · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Kazuhiro MochizukiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, 960-1295, Fukushima City, Japan. mochi-k@fmu.ac.jp.ORCID http://orcid.org/0000-0001-6685-2378
Shogo KobayashiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, 960-1295, Fukushima City, Japan.
Nobuhisa TakahashiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, 960-1295, Fukushima City, Japan.
Kotaro SugimotoDepartment of Basic Pathology, Fukushima Medical University, Fukushima, Japan.
Hideki SanoDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, 960-1295, Fukushima City, Japan.
Yoshihiro OharaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, 960-1295, Fukushima City, Japan.
Shin MineishiDepartment of Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
Yi ZhangFels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, USA.
Atsushi KikutaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, 960-1295, Fukushima City, Japan.
Fukushima Medical University Hospital · JPFukushima Medical University · JPPenn State Milton S. Hershey Medical Center · USTemple University · US

Funding

Japan Society for the Promotion of Science JP15K09659Japan Society for the Promotion of Science JP19K07754
6 · The paper itself

Abstract

backgroundCancer vaccines that induce endogenous antitumor immunity represent an ideal strategy to overcome intractable cancers. However, doing this against a pre-established cancer using autologous immune cells has proven to be challenging. "Allogeneic effects" refers to the induction of an endogenous immune response upon adoptive transfer of allogeneic lymphocytes without utilizing hematopoietic stem cell transplantation. While allogeneic lymphocytes have a potent ability to activate host immunity as a cell adjuvant, novel strategies that can activate endogenous antitumor activity in cancer patients remain an unmet need. In this study, we established a new method to destroy pre-developed tumors and confer potent antitumor immunity in mice using alloantigen-activated CD4

methodsAAA-CD4

resultsUpon intratumoral injection, these AAA-CD4

conclusionsOur findings indicate that AAA-CD4

Indexed as

AnimalsCD4-Positive T-LymphocytesDisease Models, AnimalHumansImmunotherapyIsoantigensMiceIsoantigensAllogeneic CD4+ T-cellCancer immunotherapyCancer vaccineDendritic cellEndogenous CD8+ cytotoxic T-cell

Identifiers

PMID34625113
PMCPMC8499505
OpenAlexW3204668091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.